Response to Levrier re: Human Germline and Heritable Genome Editing: The Global Policy Landscape
By Marcy Darnovsky, Katie Hasson, and Timothy M. Krahn,
The CRISPR Journal
| 02. 19. 2021
In response to: https://www.liebertpub.com/doi/10.1089/crispr.2021.29121.gle
Levrier apparently misunderstands the nature of our project published in The CRISPR Journal in October 2020.1 We identified and reviewed policy documents relevant to human germline and heritable genome editing research in 96 countries. We did not speculate about arguments that might lead legislatures or courts to revise existing policies or adjudicate prospective cases, nor did we attempt to examine each policy in its national or international context. Rather, based on close and careful readings of the identified texts, we categorized countries according to the current permissibility or impermissibility of germline and heritable genome editing. Then, we counted.
We welcome corrections and additions to the data we have compiled, which we plan to keep updated at https://tinyurl.com/HumanGenomeEditingPolicies. Unfortunately, Levrier does not provide appropriate documentation for his challenge to our categorizations regarding human germline and heritable genome editing research in three countries (France, Mexico, and Japan). Instead, he points to a report, unspecified “debates” in the French parliament, and comments on social media. We sometimes used such sources to identify relevant policy documents, but did...
Related Articles
By Rob Stein, NPR | 12.13.2024
Lucy Landman was born with a very rare genetic disorder that causes severe intellectual disability, weak muscles and seizures, among other symptoms.
"She is expected to very much never be able to live independently, likely never be potty trained...
By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024
In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...
By Staff, Reuters | 12.04.2024
The Centers for Medicare & Medicaid Services said on Wednesday it had entered into agreements with Vertex Pharmaceuticals (VRTX.O), opens new tab and bluebird bio (BLUE.O), opens new tab to help increase patient access to their gene therapies.
The so-called...
Flag of South Africa; design by Frederick Brownell,
image by WikimediaCommons users.
Public domain, via Wikimedia Commons
What is the legal status of heritable human genome editing (HHGE)? In 2020, a comprehensive policy analysis by Baylis, Darnovsky, Hasson, and Krahn documented that more than 70 countries and an international treaty prohibit it, and that no country explicitly permits it. Policies in some countries were non-existent, ambiguous, or subject to possible amendment, but the general rule remained, even after one...